Genome-wide association studies and genetic risk assessment of liver diseases

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 12, 2010, Pages 669-681

  Krawczyk, Marcin ^a   Müllenbach, Roman ^a   Weber, Susanne N ^a   Zimmer, Vincent ^a   Lammert, Frank ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CCR5; INOSINE TRIPHOSPHATE; TRANSFORMING GROWTH FACTOR BETA; WILSON DISEASE PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHOLELITHIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; GENE DISRUPTION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HEMOCHROMATOSIS; HEPATITIS C; HOMOZYGOSITY; HUMAN; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER DISEASE; MACHINE LEARNING; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; POLYMERIZATION; PRACTICE GUIDELINE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENE; WILSON DISEASE;

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIVER DISEASES; RISK FACTORS;

EID: 78649903976     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.170     Document Type: Review

References (142)

1. Lammert, F. in Textbook of Hepatology: From Basic Science to Clinical Practice (eds Rodés, J., Benhamou, J.-P, Blei, A., Reichen, J. & Rizzetto, M.) 371-383 (Blackwell Publishing, Oxford, 2007).
2. Cordell, H. J. Detecting gene-gene interactions that underlie human diseases. Nat. Rev. Genet. 10, 392-404 (2009).
3. Human Genetics Commission. A common framework of principles for direct-to-consumer genetic testing services [online], http://www.hgc.gov. uk/Client/document.asp?Docld=280&CAtegorvld=10 (2010).
4. Sheldon, J. H. Haemochromatosis (Oxford University Press, London, 1935).
5. Feder, J. N. et al. The discovery of the new haemochromatosis gene. J. Hepatol. 38, 704-709 (2003).
6. Zerres, K. in Was ist uns die Gesundheit wert? Gerechte Verteilung knapper Ressourcen (eds Schumpelick, V. & Vogel, B.) 97-108 (Herder Verlag, Freiburg, 2007).
7. Feder, J. N. et al. A novel MHC class Hike gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13, 399-408 (1996).
8. Villanueva, A., Newell, P & Hoshida, Y. Inherited hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 24, 725-734 (2010).
9. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J. Hepatol. 53, 3-22 (2010).
10. UK Genetic Testing Network [online], http://www.ukgtn. nhs.uk (2010).
11. Bensaid, M. et al. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 126, 1400-1408 (2004).
12. Rochette, J., Le Gac, G., Lassoued, K., Ferec, C. & Robson, K. J. Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum. Genet. 128, 233-248 (2010).
13. rd edn (eds Killenberg, P G. & Clavien, PA.) 172-194 (Blackwell, Maiden, MA, 2006).
14. 1-antitrypsin deficiency. Scand. J. Clin. Lab. Invest. 15, 132-140 (1963).
15. Herrmann, U., Dockter, G. & Lammert, F. Cystic fibrosis-associated liver disease. Best Pract. Res. Clin. Gastroenterol. 24, 585-592 (2010).
16. 1-Antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J. Clin. Invest. 110, 1585-1590 (2002).
17. Rudnick, D. A. & Perlmutter, D. H. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 42, 514-521 (2005).
18. 1-Antitrypsin deficiency. Lancet 365, 2225-2236 (2005).
19. Fischer, H. P., Ortiz-Pallardó, M. E., Ko, Y., Esch, C. & Zhou, H. Chronic liver disease in heterozygous αl-antitrypsin deficiency PiZ. J. Hepatol. 33, 883-892 (2000).
20. Bartlett, J. R. et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 302, 1076-1083 (2009).
21. Bowlus, C. L. et al. Factors associated with advanced liver disease in adults with alphalantitrypsin deficiency. Clin. Gastroenterol. Hepatol. 3, 390-396 (2005).
22. Mencin, A. et al. Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology 46, 1443-1452 (2007).
23. Bull, P C., Thomas, G. R., Rommens, J. M., Forbes, J. R. & Cox, D. W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet 5, 327-337 (1993).
24. Huster, D. Wilson disease. Best Pract. Res. Clin. Gastroenterol, (in press).
25. Department of Medical Genetics at the University of Alberta. Wilson Disease Mutation Database [online], http://www.wilsondisease.med.ualberta.ca/ database.asp (2010).
26. Ferenci, P. et al. Late-onset Wilson's disease. Gastroenterology 132, 1294-1298 (2007).
27. Gow, P J. et al. Diagnosis of Wilson's disease: an experience over three decades. Gut 46, 415-419 (2000).
28. Roberts, E. A. & Schilsky, M. L. Diagnosis and treatment of Wilson disease: an update. Hepatology 47, 2089-2111 (2008).
29. Xuan. A., Bookman, I., Cox, D. W. & Heathcote, J. Three atypical cases of Wilson disease: assessment of the Leipzig scoring system in making a diagnosis. J. Hepatol. 47, 428-433 (2007).
30. Weiss, K. H. et al. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J. Inherit. Metab. Dis. doi:10.1007/S10545-010-9123-5.
31. Rogowski, W. H. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. Med. Decis. Making 29, 224-238 (2009).
32. Schofski, O., Schmidtke, J. & Stuhrmann, M. Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genet. 3, 2-11 (2000).
33. Stuhrmann, M., Hoy, L., Nippert, I. & Schmidtke, J. Genotype-based screening for hereditary hemochromatosis: II. Attitudes toward genetic testing and psychosocial impact-a report from a German pilot study. Genet. Test. 9, 242-254 (2005).
34. Bryant, J. et al. Diagnostic strategies using DNA testing for hereditary haemochromatosis in atrisk populations: a systematic review and economic evaluation. Health Technol. Assess. 13, 1-126 (2009).
35. Elsass, P., Pedersen, P., Husum, K. & Milman, N. Assessment of the psychological effects of genetic screening for hereditary hemochromatosis. Ann. Hematol. 87, 397-404 (2008).
36. Phatak, P D., Bonkovsky, H. L. & Kowdley, K. V. Hereditary hemochromatosis: time for targeted screening. Ann. Intern. Med. 149, 270-272 (2008).
37. Adams, P. C. & Barton, J. C. Haemochromatosis. Lancet 37, 1855-1860 (2007).
38. McLaren, G. D. & Gordeuk, V. R. Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Hemato/ogyAm. Soc. Hematol. Educ. Program 2009, 195-206 (2009).
39. Acton, R. T. et al. A genome-wide linkage scan for iron phenotype quantitative trait loci: the HEIRS Family Study. Clin. Genet. 71, 518-529 (2007).
40. Zondervan, K. T. & Cardon, L. R. The complex interplay among factors that influence allelic association. Nat. Rev. Genet. 5, 89-100 (2004).
41. Bodmer, W. & Bonilla, C. Common and rare variants in multifactorial susceptibility to common diseases. Nat. Genet. 40, 695-701 (2008).
42. Raber, J., Huang, Y. & Ashford, J. W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641-650 (2004).
43. Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Invest. 115, 209-218 (2005).
44. Weber, S., Gressner, O. A., Hall, R., Grunhage, F & Lammert, F. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans. Clin. Liver Dis. 12, 747-757 (2008).
45. Weber, S., Grunhage, F., Hall, R. & Lammert, F Genome-wide association studies in hepatology [German]. Z. Gastroenterol. 48, 56-64 (2010).
46. loannidis, J. P., Trikalinos, T. A., Ntzani, E. E. & Contopoulos-loannidis, D. G. Genetic associations in large versus small studies: an empirical assessment. Lancet 361, 567-571 (2003).
47. Bataller, R., North, K. E. & Brenner, D. A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37, 493-503 (2003).
48. Falleti, E. et al. TGF-β1 genotypes in cirrhosis: relationship with the occurrence of liver cancer. Cytokine 44, 256-261 (2008).
49. Gewaltig, J., Mangasser-Stephan, K., Gartung, C., Biesterfeld, S. & Gressner, A. M. Association of polymorphisms of the transforming growth factor-β1 gene with the rate of progression of HCV-induced liver fibrosis. Clin. Chim. Acta 316, 83-94 (2002).
50. Powell, E. E. et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31, 828-833 (2000).
51. Tag, C. G. et al. Analysis of the transforming growth factor-β1 (TGF-β1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection. Cytokine 24, 173-181 (2003).
52. Wang, H. et al. Transforming growth factor-beta 1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J. Gastroenterol. 11, 1929-1936 (2005).
53. Karlsen, T H., Melum, E. & Franke, A. The utility of genome-wide association studies in hepatology. Hepatology 51, 1833-1842 (2010).
54. Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human disease. Science 322, 881-888 (2008).
55. Manolio, T. A., Brooks, L. D. & Collins, F S. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118, 1590-1605 (2008).
56. Hindorff, L. A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362-9367 (2009).
57. National Human Genome Research Institute. A catalog of published genome-wide association studies [online], http://www.genome.gov/26525384 (2010).
58. Lammert, F & Sauerbruch, T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 423-433 (2005).
59. Katsika, D. et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43, 141 twin pairs. Hepatology 41, 1138-1143 (2005).
60. Buch, S. et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 39, 995-999 (2007).
61. Yu, L. et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 110, 671-680 (2002).
62. Wang, D. Q., Cohen, D. E. & Carey, M. C. Biliary lipids and cholesterol gallstone disease. J. Lipid Res. 50 (Suppl.), S406-S411 (2009).
63. Lammert, F., Carey, M. C. & Paigen, B. Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map. Gastroenterology 120, 221-238 (2001).
64. Lyons, M. A. & Wittenburg, H. Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology 131, 1943-1970 (2006).
65. Wasmuth, H. E. et al. Coinheritance of Gilbert syndrome-associated UGT1A1 mutation increases gallstone risk in cystic fibrosis. Hepatology 43, 738-741 (2006).
66. Buch, S. et al. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology doi:10.1053/j.gastro.2010.09.003.
67. Sanna. S. et al. Common variants in the SLC01B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum. Mol. Genet. 18, 2711-2718 (2009).
68. Johnson, A. D. et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum. Mol. Genet. 18, 2700-2710 (2009).
69. Lin, J. P. et al. Conditional linkage and genomewide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels-the Framingham Heart Study. Atherosc/erosis 206, 228-233 (2009).
70. Ostrow, J. D. Unconjugated bilirubin and cholesterol gallstone formation. Hepatology 12, 219S-226S (1990).
71. Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461-1465 (2008).
72. He, S. et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285, 6706-6715 (2010).
73. Bathum, L. et al. Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clin. Chem. 47, 81-87 (2001).
74. Whitfield, J. B., Zhu, G., Nestler, J. E., Heath, A. C. & Martin, N. G. Genetic covariation between serum gamma-glutamyl transferase activity and cardiovascular risk factors. Clin. Chem. 48, 1426-1431 (2002).
75. Tian, C., Stokowski, R. P., Kershenobich, D., Ballinger, D. G. & Hinds, D. A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 42, 21-23 (2010).
76. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
77. Chalasani, N. et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology doi:10.1053/j.gastro.2010.07.057.
78. Hirschfield, G. M. et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N. Engl. J. Med. 360, 2544-2555 (2009).
79. Liu, X. et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 42, 658-660 (2010).
80. Karlsen. T. H. et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 138, 1102-1111 (2010).
81. Karlsen. T. H. Primary sclerosing cholangitis. Best Pract Res. Clin. Gastroenterol. 24, 655-666 (2010).
82. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
83. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 41, 1100-1104 (2009).
84. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 41, 1105-1109 (2009).
85. Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009).
86. Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-1345 (2010).
87. Fellay, J. et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464, 405-408 (2010).
88. Kamatani, Y. et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41, 591-595 (2009).
89. Frodsham, A. J. et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl Acad. Sci. USA 103, 9148-9153 (2006).
90. Zhang, H. et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 42, 755-758 (2010).
91. *5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41, 816-819 (2009).
92. Singer, J. B. et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42, 711-714 (2010).
93. Kindmark, A. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenoinics J. 8, 186-195 (2008).
94. Hillebrandt, S. et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37, 835-843 (2005).
95. Hillebrandt, S., Goos, C., Matern, S. & Lammert, F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfibl on chromosome 15. Gastroenterology 123, 2041-2051 (2002).
96. Overall, R. W. et al. Genetics of the hippocampal transcriptome in mouse: a systematic survey and online neurogenomics resource. Front Neurosci. 3, 55 (2009).
97. Gatti, D. et al. Genome-level analysis of genetic regulation of liver gene expression networks. Hepatology 46, 548-557 (2007).
98. Schughart, K. et al. SYSGEN ET: a meeting report from a new European network for systems genetics. Mamm. Genome 21, 331-336 (2010).
99. Churchill, G. A. et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet. 36, 1133-1137 (2004).
100. Flint, J. & Mott, R. Applying mouse complex-trait resources to behavioural genetics. Nature 456, 724-727 (2008).
101. Rockman, M. V. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
102. Chen, y et al. Variations in DNA elucidate molecular networks that cause disease. Nature 452, 429-435 (2008).
103. Argmann, C. A., Chambon, R & Auwerx, J. Mouse phenogenomics: the fast track to "systems metabolism". Cell Metab. 2, 349-360 (2005).
104. Peters, L. L. et al. The mouse as a model for human biology: a resource guide for complex trait analysis. Nat Rev. Genet 8, 58-69 (2007).
105. Burgess-Herbert, S. L. et al. An experimental assessment of in silico haplotype association mapping in laboratory mice. BMC Genet. 10, 81 (2009).
106. Cervino, A. C., Darvasi, A., Fallahi, M., Mader, C. C. & Tsinoremas, N. F. An integrated in silico gene mapping strategy in inbred mice. Genetics 175, 321-333 (2007).
107. Plomin, R., Haworth, C. M. & Davis, O. S. Common disorders are quantitative traits. Nat. Rev. Genet 10, 872-878 (2009).
108. Richardson, M. M. et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J. Med. Genet 42, e45 (2005).
109. Huang, H. et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46, 297-306 (2007).
110. Guo, J. et al. Functional linkage of cirrhosispredictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49, 960-968 (2009).
111. Li, y et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J. Hepatol. 51, 750-757 (2009).
112. Marcolongo, M. et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 50, 1038-1044 (2009).
113. Pradat, R et al. The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 51, 356-357 (2010).
114. Wei, Z. et al. From disease association to risk assessment: an optimistic view from genomewide association studies on type 1 diabetes. PLoS Genet. 5, el000678 (2009).
115. Kotronen, A. et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137, 865-872 (2009).
116. Pawitan, Y., Seng, K. C. & Magnusson, P K. How many genetic variants remain to be discovered? PLoS ONE 4, e7969 (2009).
117. Kraft, R & Hunter, D. J. Genetic risk predictionare we there yet? N. Engl. J. Med. 360, 1701-1703 (2007).
118. Gibson, G. Hints of hidden heritability in GWAS. Nat Genet 42, 558-560 (2010).
119. Wray, N. R., Goddard, M. E. & Visscher, R M. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 17, 1520-1528 (2007).
120. Wray, N. R., Yang, J., Goddard, M. E. & Visscher, R M. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet. 6, el000864 (2010).
121. Xu, J. et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 69, 1565-1572 (2009).
122. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
123. Grunhage, F. et al. Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C. J. Hepatol. 52, 153-159 (2010).
124. Thomas, D. Gene-environment-wide association studies: emerging approaches. Nat Rev. Genet 11, 259-272 (2010).
125. Ashley, E. A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
126. Ormond, K. E. et al. Challenges in the clinical application of whole-genome sequencing. Lancet 375, 1749-1751 (2010).
127. Hogarth, S., Javitt, G. & Melzer, D. The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu. Rev. Genomics Hum. Genet 9, 161-182 (2008).
128. McBride, C. M. et al. Putting science over supposition in the arena of personalized genomics. Nat Genet 40, 939-942 (2008).
129. Gulcher, J. & Stefansson, K. Genetic risk information for common diseases may indeed be already useful for prevention and early detection. Eur. J. Clin. Invest 40, 56-63 (2010).
130. Cassiman, D. & Jaeken, J. NASH may be trash. Gut 57, 141-144 (2008).
131. [No authors listed] Positively disruptive. Nat. Genet 40, 119 (2008).
132. Office of Science Policy, National Institutes of Health. Direct-to-consumer genetic testing. Report of the Secretary's Advisory Committee on Genetics, Health, and Society [online], http://oba.od.nih.gov/oba/sacghs/ reports/SACGHSPTCReport2010.pdf (2010).
133. Personal Genome Project [online], http://www.personalgenomes.org/(2010).
134. Church, G. M. The personal genome project. Mol. Syst Biol. 1, 2005.0030 (2005).
135. Centers for Disease Control and Prevention. Genomic Translation [online], http://www.cdc.gov/genomics/gtesting/ACCE/index.htm (2010).
136. Ransohoff, D. F. & Khoury, M. J. Personal genomics: information can be harmful. Eur. J. Clin. Invest 40, 64-68 (2010).
137. 1000 Genomes. A Deep Catalog of Human Genetic Variation [online], http://www.1000genomes.org (2010).
138. McCarthy, M. I. et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet 9, 356-369 (2008).
139. Huang, H. et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130, 1679-1687 (2006).
140. Yuan, X. et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J. Hum. Genet. 83, 520-528 (2008).
141. Melzer, D. et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 4, el000072 (2008).
142. Ochi, H. et al. Inosine triphosphate pyrophophatase polymorphism affects ribavirininduced anemia and outcome of therapy-a genome-wide study of Japanese hepatitis C virus patients. Gastroenterology 139, 1190-1197 (2010).